Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
– 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 – Reiterating FY22 net sales guidance of $510 to $560 million – FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO, May 04, 2022–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced […]